Lynch syndrome: barriers to and facilitators of screening and disease management

Table 1 Participant characteristics (N = 23)

ID	*Family*	*Gender*	*Post-GT* ^a	*Age* ^b	*Affected*	*Onset Age*	*Cancer Types* ^c
23	1B	Female	6.42	57	No	---	---
24	1B	Female	6.42	78	Yes	46	CRC/EC
25	1B	Male	8.50	52	Yes	42	CRC/GA
26	1B	Female	2.42	32	No	---	---
31	1B	Male	7.50	47	Yes	45	CRCx2
8	1C	Male	3.67	28	No	---	---
22	1C	Male	6.50	26	No	---	---
30	1C	Male	7.42	57	No	---	---
9	2A	Female	8.08	41	Yes	39	CRCx2
32	2A	Female	9.58	69	Yes	35	CRCx2/EC/GA/SK
20	2B	Female	9.08	50	Yes	33	EC/BR/VA
21	2C	Male	9.08	50	No	---	---
10	3A	Female	7.00	42	No	---	---
27	3A	Female	8.17	51	Yes	43	Ovarian
28	3A	Male	8.17	43	Yes	45	CRC/DUO
29	3A	Female	7.50	33	No	---	---
11	3B	Male	8.42	76	Yes	39	CRCx2/SK/KD
4	6	Female	0.75	48	Yes	49	CRC
19	6	Female	0.08	63	Yes	54	SK
37	7	Female	3.17	50	Yes	46	KD/EC
38	7	Male	3.08	46	No	---	---
34	8	Female	2.83	43	Yes	40	EC
36	8	Female	3.75	42	No	---	---

Note. Families 1B to 3B have the intron 5 mutation and families 6 to 8 have the exon 8 deletion. The use of A, B or C after the family number denotes separate nuclear families within a particular extended family.
^a Years since genetic testing.
^b Age at first interview.
^c CRC = colorectal; EC = endometrial; GA = gastric; SK = skin; BR = breast; VA = vaginal;
KD = kidney; DUO = duodenal.

ISSN: 1897-4287